[The peculiarities of the evaluation of the severity of the harm to health in the case of development of psychic problems associated with the concomitant HIV infection and the accompanying infectious pathology].

The objective of the present study was to elaborate the qualifying criteria for the evaluation of the severity of the harm to health in the case of development of a psychic disease associated with the concomitant HIV infection and the accompanying infectious pathology, in the first place tuberculosis, venereal diseases, parenteral hepatitis B and C. The scientifically substantiated qualifying criteria are proposed to be used for the expert assessment of the harm to health in the case of development a psychic disease associated with the concomitant HIV infection and the accompanying infectious pathology.

[Comparison of efficacy of trileptal (oxcarbazepine) and carbamazepine in the treatment of temporal epilepsy].

An aim of the study was to compare the spectrum of effects of oxcarbazepine and carbamazepine in patients with partial temporal epilepsy. Seventy-two patients (24 men and 48 women) diagnosed with cryptogenic partial epilepsy have been examined. Fifty-one patients received carbamazepine as a monotherapy in dosage 300-1200 mg/day, 21 patients were treated with oxcarbazepine in dosage 600-1500 mg daily. The results revealed the similar effects of two drugs. However some differences were also found: the effect of oxcarbazepine on complex partial seizures was more pronounced comparing to carbamazepine. These differences became evident after the first month of therapy and were related only with part of the reduction of complex partial seizures after 1, 2, and 3 month of therapy. The highest levels of significance for these differences for the complete reduction of complex partial seizures (a control over seizures) were observed after 2 and 3 months of therapy. During the therapy, oxcarbazepine was more effective than carbamazepine in the reduction of refractory complex partial seizures. In conclusion, oxcarbazepine can be considered as a drug of choice in the treatment of complex partial seizures in patients with partial epilepsy.

[A use of Magne-B6 in the treatment of anxiety-depressive states in patients with epilepsy]. / Primenenie preparata Magne-B6 dlia lecheniia trevozhno-depressivnykh sostoianii u bol'nykh épilepsiei.

Magne-B6 was used, together with anticonvulsive therapy, in the treatment of 25 patients with different forms of epilepsy. In all cases, psychiatric status of patients featured by depression, anxiety and some psychotic sighs. The drug was prescribed in the mean therapeutic dose during 28 days. Along with psychopathologic examination, a psychometric method, using self-rating scales for Zung anxiety and depression scale, SCL-90 and Global clinical impression (CGI) scale, was administered. Magne-B6 exerted a positive non-specific influence on patient's mental state, especially with regard to affective disorders. The positive effect of the drug emerged on 14th day of the treatment and achieved a statistically significant level to 28th day. The medication was more effective in asthenic and subdepressive syndromes, in encephalopathic syndrome the efficacy was lower. The drug was well tolerated and did not cause any side effects.

[Topamax monotherapy of partial epilepsy]. / Monoterapiia partsial'nykh form épilepsii topamaksom.

Thirty patients diagnosed with partial epilepsy (PE): 17 cases with cryptogenic PE, 11--with symptomatic PE and 2--with symptomatic generalized PE, have been switched to topamax monotherapy, in dosage 50-200 mg daily, for 3 months. A type of seizures--simple partial, complex partial and secondary generalized, was taken into account, when considering topamax efficacy. A complete elimination of seizures was achieved after 3 months treatment in 80% of the cases, the mostly pronounced effect being demonstrated for secondary generalized seizures. A decrease of seizures frequency was shown for all types, but in simple partial and secondary generalized seizures the effect emerged earlier (after 1 month of the treatment) comparing to complex partial seizures. Good tolerability of topamax was observed.

[Topamax in the treatment resistance partial epilepsy]. / Primenenie topamaksa pri lechenii rezistentnoi partsial'noi épilepsii.

Twenty-five epileptic patients, mean age 25.7 years, have been studied. Twenty-two of them were diagnosed with symptomatic partial epilepsy, 1--with criptogenic partial epilepsy and 2--with idiopathic partial epilepsy. Illness duration was estimated as follows: above 5 years--5 patients, above 10 years--10, above 20 years--4 and less than 5 years--6. Polymorphic seizures were detected in 56% of the cases and monomorphic ones, resistant to the previous traditional anticonvulsant therapy,--in 44%. Topamax was used as an add-on therapy to the previously prescribed anticonvulsants in initial dose of 25 mg daily, with a following continuous dose increase. The mean therapeutic dosage was 100 mg daily. Therapeutic efficacy was assessed during 3 months. Since 1 month of topamax adjunction to a treatment schedule, a mean frequency of all types of seizures was reduced. The best effect was found in the case of combination of simple partial and secondary generalized seizures. The medication was effective in 60-80% of the patients with strong resistance to traditional anticonvulsants. Topamax is concluded to be a highly effective antiepileptic medication, which gives new possibilities for a treatment of patients with partial epilepsy resistant to traditional drugs.

[Suicide risk factors in epileptic patients]. / Faktory riska razvitiia suitsidal'nogo povedeniia u bol'nykh épilepsiei.

In search for risk factors of suicide behavior in epileptic patients one hundred and five patients were examined, including those with (70) and without (35) suicide behavior. Risk factors of suicide behavior encompassed the presence of co-morbid organic affective disorder and a combination of pronounced epileptoid type personality changes and epileptic cognitive deterioration. High frequency of primary generalized seizures and polymorphic seizures combination and typical anticonvulsants daily dosage, including phenobarbital, correlated with suicidal behavior. On the contrary, high frequency of complex partial seizures and high dosage of valproate derivatives and carbamazepin negatively correlated with a risk of suicidal behavior in epileptic patients. Comparing to phenobarbital, novel anticonvulsants--valproic acid derivatives, carbamazepin, lamotrigine--are superior in epilepsy treatment to prevent suicidal behavior.